DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
Cydan Raises $34M to Advance New Therapies for Sickle Cell, Other Rare Diseases
Cydan, the company that founded Imara — which developed a sickle cell disease (SCD) treatment candidate, IMR-687 — has raised $34 million in new financing to advance innovative therapies for patients living with SCD and other rare diseases.
Cydan, based in Cambridge, Massachusetts, identifies promising scientific findings and drug candidates and advances them into clinical development. Cydan also establishes independent companies to promote selected therapies through clinical development and regulatory approval. In this round of financing, a new investor, Longitude Capital, joined existing investors New Enterprise Associates (NEA), Pfizer Venture Investments, Alexandria Venture Investments and Lundbeckfond Ventures.
+myBinderRelated Content
-
education & researchHydroxyurea: A Treatment Option for Sickle Cell DiseaseHydroxyurea is a chemotherapy drug used ...
-
videos & visualsDeveloping Hydroxyurea, the First FDA-Approved Therapy for Sickle Cell Diseasehttps://www.youtube.com/watch?v=0kIz5ZKy...
-
news & eventsSickle Cell Treatment ‘Life-Changing’ for Brockton BrothersEmmanuel “Manny” Johnson, 21, of Bro...
-
news & eventsNew Sickle Cell Disease Research Shows Improved Patient OutcomesEmerging therapies and promising new ins...
-
news & eventsCRISPR could end sickle cell disease, but signing up black patients for clinical trials will be a hard sellThe first attempts to use a groundbreaki...
-
news & eventsSickle Cell Disease Association of America, Inc. and Hemanext® Inc. Form New Strategic PartnershipSickle Cell Disease Association of Ameri...
-
education & researchDisability evaluation under social security (hematological disorders-adult)A. What hematological disorders do we ev...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.